5666-21-7

Basic information

• Product Name: ALLYLPROPYLAMINE
• Synonyms: ALLYLPROPYLAMINE;N-propyl-2-propen-1-amine(SALTDATA: HCl);N-prop-2-enylpropan-1-amine;N-propyl-2-propen-1-amine
• CAS NO: 5666-21-7
• Molecular Formula: C₆H₁₃N
• Molecular Weight: 99.17
• Mol File: 5666-21-7.mol
• Article Data: 9

Chemical Properties

• Boiling Point: 125.71°C (estimate)
• Appearance: /
• Density: 0.7708
• Refractive Index: 1.4140
• CAS DataBase Reference: ALLYLPROPYLAMINE(CAS DataBase Reference)
• NIST Chemistry Reference: ALLYLPROPYLAMINE(5666-21-7)
• EPA Substance Registry System: ALLYLPROPYLAMINE(5666-21-7)

Safety Data

• Hazardous Substances Data: 5666-21-7(Hazardous Substances Data)

Usage

General Description

Allylpropylamine is a chemical compound that consists of an allyl group, a propyl group, and an amine group. It is a clear, colorless liquid with a strong ammonia-like odor. Allylpropylamine is primarily used as a raw material in the synthesis of various chemicals and is also used as a crosslinking agent in the production of polymers and resins. It is classified as a hazardous substance due to its potential to cause skin and eye irritation, as well as respiratory issues. Allylpropylamine is primarily handled and used in industrial settings under strict safety measures to prevent exposure and minimize any potential health risks.

Upstream product

• 107-08-4 1-iodo-propane 
• 107-11-9 1-amino-2-propene 
• 107-10-8 propylamine 
• 106-95-6 allyl bromide 
• 106-94-5 propyl bromide 
• 30532-98-0 N-propylideneallylamine 

Downstream Products

• 41063-30-3 1-(n-propylamino)-2-propanol 
• 875762-88-2 C₁₅H₁₉NO₃ 
• 1333-74-0 hydrogen 
• 121-44-8 triethylamine 
• 32386-50-8 1-propyl-1,2-azaborolidine 
• 444325-29-5 Allyl-[6-chloro-2-trifluoromethyl-7-(2,4,6-trimethyl-phenyl)-7H-imidazo[1,2-a]imidazol-3-ylmethyl]-propyl-amine 
• 819800-25-4 trans-N-propyl-3-chloro-4-chloromethyl-3-methyl-pyrrolidin-2-one 
• 819800-25-4 cis-N-propyl-3-chloro-4-chloromethyl-3-methyl-pyrrolidin-2-one 
• 78286-62-1 N²-Phenyl-N¹-propyl-propane-1,2-diamine 
• 38825-94-4 p-(N-Propyl-N-2-propenylsulfamoyl)benzoesaeure 

Relevant articles and documents

Sequence-defined polymers via orthogonal allyl acrylamide building blocks

Biological systems have long recognized the importance of macromolecular diversity and have evolved efficient processes for the rapid synthesis of sequence-defined biopolymers. However, achieving sequence control via synthetic methods has proven to be a difficult challenge. Herein we describe efforts to circumvent this difficulty via the use of orthogonal allyl acrylamide building blocks and a liquid-phase fluorous support for the de novo design and synthesis of sequence-specific polymers. We demonstrate proof-of-concept via synthesis and characterization of two sequence-isomeric 10-mer polymers. 1H NMR and LCMS were used to confirm their chemical structure while tandem MS was used to confirm sequence identity. Further validation of this methodology was provided via the successful synthesis of a sequence-specific 16-mer polymer incorporating nine different monomers. This strategy thus shows promise as an efficient approach for the assembly of sequence-specific functional polymers.

Synthesis and biological evaluation of novel isopropanolamine derivatives as non-peptide human immunodeficiency virus protease inhibitors

Novel potential human immunodeficiency virus (HIV) protease inhibitors were designed by a combination of nelfinavir and amprenavir motifs. The designed compounds were prepared by a facile synthetic route and their stereochemistry was further confirmed by

MACROCYCLIC BETA-SECRETASE INHIBITORS

Disclosed are novel compounds of the formula (I): or a pharmaceutically acceptable salt or solvate thereof, wherein R1, R2, R3, n and X are as defined in the specification. Also disclosed are pharmaceutical compositions comprising the compounds of formula (I). Also disclosed are methods of treating cognitive or neurodegenerative diseases such as Alzheimer's disease. Also disclosed are methods of treating a cognitive or neurodegenerative disease comprising administering to a patient I need of such treatment a combination of at least one compound of formula (I) and at least one compound selected from the group consisting of -secretase inhibitors other than those of formula (I), HMG-CoA reductase inhibitors, gamma-secretase inhibitors, non-steroidal anti-inflammatory agents, N-methyl-D-aspartate receptor antagonists, cholinesterase inhibitors and anti-amyloid antibodies.